Pura Vida Investments’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
Other funds holding NTLA
AIM
NAMA
Pura Vida Investments's NTLA Position: Q2 2022 in Review
Pura Vida Investments sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 104,073 shares — an estimated $5.28M sold.
Pura Vida Investments first reported a position in NTLA in Q1 2021 and held it in 5 quarters. The position peaked at $34.8M in Q2 2021. 300 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.
- Pura Vida Investments reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
- Pura Vida Investments sold 104,073 Intellia Therapeutics shares in Q2 2022, an estimated $5.28M.
- Pura Vida Investments first reported a position in Intellia Therapeutics in Q1 2021 and held it in 5 quarters.
- Pura Vida Investments's Intellia Therapeutics position peaked at $34.8M in Q2 2021.
- 300 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.
Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.